Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, understanding the financial health of a company is crucial. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two industry players: Novo Nordisk A/S and ImmunityBio, Inc., from 2014 to 2023.

Novo Nordisk, a Danish multinational, consistently outpaces ImmunityBio in SG&A spending, reflecting its expansive global operations. In 2023, Novo Nordisk's SG&A expenses reached approximately 61.6 billion, marking a 130% increase from 2014. This growth underscores its strategic investments in marketing and administration to maintain its market leadership.

Conversely, ImmunityBio, a smaller biotech firm, shows a more volatile trend. Its SG&A expenses peaked in 2015, with a notable 5,130% increase from the previous year, before stabilizing around 130 million in 2023. This fluctuation highlights the challenges faced by emerging companies in managing operational costs while striving for innovation.